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Objectives: Fetal growth restriction is associated with chronic fetal hypoxia, poor perinatal 
outcome and increased perinatal mortality. There are no reliable methods to detect cell 
damage in the central nervous system (CNS) in these patients. The findings of increased an 
acidic calcium-binding protein (S100B) concentration in biological fluids of infants after 
brain injury have supported the use of S100B as a biochemical marker of CNS damage. 
The purpose of the study was to assess blood S100B concentrations in small for gestational 
age (SGA) and appropriate for gestational age (AGA) newborns and to evaluate the 




Material and methods: The investigation was carried out between November 2011 and April 
2014. Serum S100B protein level was assessed in cord blood collected from newborns after 
birth. Medical records of mothers of neonates studied were reviewed for pregnancy induced 
hypertension (PIH), preeclampsia, maternal smoking during pregnancy and abnormalities in 
umbilical artery (UA) Doppler ultrasound examination. 
Results: The study was carried out in 88 SGA neonates and 80 AGA neonates. The median 
value of S100B protein concentration in the SGA study group was significantly higher than in 
AGA controls (p < 0.001). Cord blood serum S100B concentration in SGA neonates with 
prenatal normal UA Doppler ultrasound findings (n = 32) did not differ from that SGA 
neonates with abnormal prenatal UA Doppler findings (n = 25) (p = 0.74), but was 
significantly higher than in AGA newborns (p < 0.001). 
Conclusions: Elevated S100B protein levels in cord blood collected from SGA newborns 
may be helpful in detecting infants at higher risk of postnatal neurologic disturbances at an 
early stage.  





Department of Neonatology, Children Clinical Hospital, Medical University of Warsaw, 63A 
Żwirki i Wigury St, 02–091 Warsaw, Poland 





Small for gestational age (SGA) neonates have been defined as those with birthweight 
below a threshold, the 10th centile. Infants who are SGA may suffer intrauterine fetal growth 
restriction (FGR). FGR is defined as a persistent suppression of fetal growth potential that 
occurs in response to a decrease in oxygen and nutrients supply from the mother to the fetus. 
Clinical evidence suggests that feto-placental insufficiency and fetal pre-exposure to 
decreased oxygen is associated with chronic fetal hypoxia and increased perinatal mortality 
[1]. FGR is associated with poor perinatal outcome, perinatal brain injury and is the strongest 
risk factor for an unexplained intrauterine death [2, 3]. About 15% of infants with FGR 
develop some degree of neurological damage [4, 5]. Most SGA/FGR fetuses remain 
unnoticed until birth, even when routine third-trimester ultrasound is performed [6]. However, 
not all fetuses measuring less than the 10th percentile for their gestational age are at risk for 
adverse outcomes and might be constitutionally small. Available diagnostic tools and routine 
procedures used when hypoxia is suspected (blood pH, lactate levels, cerebral ultrasound) 
may not be able to detect cell damage and subclinical lesions in the nervous system. Recently, 
novel potential biomarkers of brain injury and hypoxia have been identified [7–9]. One of 
them, S100B is an acidic calcium-binding protein expressed and released by astrocytes and 
mainly concentrated in the central nervous system. Secretion of S100B is an early process of 
the glial response to metabolic injury (oxygen, serum and glucose deprivation) [9–12]. 
Previous evidence that S100B concentrations are increased in the presence of brain injury 
suggests that higher S100B levels in pregnancies with FGR reflect fetal chronic hypoxia [7, 
13, 14]. Since increased concentration of S100B can easily be found in biological fluids 
(cerebrospinal fluid, peripheral and cord blood, urine and amniotic fluid), the protein can be 




The aim of this study was to assess blood S100B concentrations in small for 
gestational age (SGA) and appropriate for gestational age (AGA) newborns and to evaluate 
the usefulness of S100B for early detection of hypoxia. We hypothesized that serum levels of 
the S100B marker might differ in SGA and AGA infants. 
 
MATERIAL AND METHODS 
Patients 
The investigation was performed in a tertiary referral center for neonatal intensive 
care. All neonates who were born SGA at the Department of Neonatology, Medical 
University of Łódź, between November 2011 and April 2014 were enrolled in the study.  
Birth weight and head circumference in newborns were measured and percentile were 
assessed. SGA was defined as birth weight ≤ 10th centile. The control group included AGA 
infants (defined as having birth weight between 10th and 90th centile) delivered consecutively 
at term. Infants who died at birth, those who had congenital malformations, and children of 
mothers who refused to participate were excluded. The gestational age of newborns was 
determined according to the date of the last menstrual period and the first trimester ultrasound 
exam. Apgar score was determined at five minutes after birth.  
SGA newborns were divided according to anthropometric indices into those with 
symmetrical and those with asymmetrical fetal growth restriction. SGA newborns have been 
categorized as “asymmetrical” when the birth weight was disproportionally restricted as 
compared to head circumference and “symmetrical” when both: weight and head 
circumference were proportionately small. Asymmetrical growth restriction was defined as 
any birth weight > 1 SD less than the corresponding head circumference. 
Medical records of mothers of neonates studied were reviewed for gestational 




umbilical artery (UA) Doppler ultrasound examination. An abnormal pulsatility index PI for 
UA was defined as above the 95th centile for gestational age for uncomplicated pregnancies. 
The study was approved by the local ethics committee (approval No. RNN/175/05/KE). 
Written informed consent was obtained from all mothers of enrolled neonates. 
Blood samples 
Cord blood was obtained from newborns directly after birth. Serum was obtained by 
centrifugation at 3000 × g for 5 min and stored at −70° C (for up to 6 months) until the 
biochemical assay. 
S100B Assay 
S100B concentrations were quantified by an enzyme-linked immunosorbent assay 
(ELISA; EIAab Science Co., Wuhan, China), according to the manufacturer’s instructions. 
Samples were analyzed in duplicate and compared with S100B standard. The lower limit of 
detection of the ELISA for S100B is 1 pg/mL. 
Statistical analysis 
Descriptive statistics were used to describe characteristics of the study group. 
Continuous data were presented as means with standard deviations (SD) or median with 
minimum and maximum values. Categorical variables were described as frequencies and 
percentages. The Shapiro-Wilk test was evaluated to determine if the data were normally 
distributed. Group comparisons for normally distributed data were performed using the t test. 
When the normality assumptions were not satisfied, Mann-Whitney U test for continuous 
variables and the Fisher’s exact test for binary variables were used. All analyses were 
performed with the use of IBM SPSS Statistics for Windows V. 25.0.0 (IBM Corp. Armonk, 






The study was carried out in 88 SGA neonates and 80 AGA neonates. Birth weight 
was lower in the SGA group than in the AGA group (p<0.001). There were no significant 
differences in maternal age, gender characteristics, mode of delivery and cord blood lactate 
concentration between the SGA and AGA groups. There was statistically significant 
difference in the Apgar score and gestational age (lower in SGA group) (Tab.1). All SGA 
infants were above or equal 32 weeks of gestation. 
None of the newborns had chromosomal abnormalities or TORCH infection. In the 
SGA group, maternal smoking during pregnancy, gestational hypertension (GH) and 
preeclampsia were observed significantly more often than in the AGA group (Tab. 1). Absent 
end-diastolic flow in UA was found in 13 cases of SGA group with abnormal prenatal 
Doppler. 
 
Table 1. Neonate and maternal demographic and obstetric characteristics of SGA and AGA 
group 
Characteristic SGA group AGA group P value 
    
Male neonates, n (%) 88 (52) 80 (56) 0.64 
Mean birth weight, g (SD) 2132 (543) 3491 (366) 0.001 
Mean gestation, weeks (SD) 37.1 (3.0) 39.1 (1.0) < 0.001 
Median Apgar score at 5 min (min–max) 10 (5–10) 10 (8–10) < 0.001 
Cord blood lactate, mg/dL (SD) 45.61 (16.1) 45.6 (14.7) 0.99 
Mean maternal age, years (SD) 31.1 (5.0) 30.0 (4.6) 0.15 
Mode of delivery, n (%)   0.13 
Spontaneous VD 20 (23) 33 (41)  




Cesarean section 67 (76) 47 (59)  
Smoking during pregnancy, n (%) 20 (23) 4 (5) 0.002 
GH, n (%) 22 (25) 3 (4) < 0.001 
Preeclampsia, n (%) 5 (6) 0 0.06 
Antenatal Doppler changes:     
PI > 95th centile in UA, n (%) 25 (28) 2 (3) < 0.001 
Absent end-diastolic flow in UA, n (%) 13 (15)   
    
 
The bold p-values highlight whether the differences observed were statistically significant. 
SD — standard deviation; SGA — small for gestational age; AGA — appropriate for 
gestational age; GH — gestational hypertension; UA — umbilical artery; VD — vaginal 
delivery 
 
Cord blood serum concentration of S100B protein at birth was significantly higher in 
the SGA infants than in the AGA group (p < 0.001) (Tab. 2). 
UA Doppler examination was performed in 57 out of 88 (65%) mothers of newborns 
from the study group. Cord blood serum S100B concentration in SGA neonates with prenatal 
normal UA Doppler ultrasound findings (n = 32, median 69.3 [0.3–463.5]) did not differ from 
that SGA neonates with abnormal prenatal UA Doppler findings (n = 25, median 44.4 [6.8–
1110.2]) (p = 0.74) but was significantly higher than in AGA newborns (n = 80) (p < 0.001) 
(Tab. 2). 
S100B concentration was significantly higher in both SGA with symmetrical (n = 29) 
and asymmetrical (n = 59) fetal growth restriction than in non-growth restricted AGA 





Table 2. Cord blood S100B concentrations in AGA, all SGA, those SGA that had normal UA 
PI and SGA newborns with symmetrical growth 
 Group N Median Min–max P value 
S100B 
(pg/mL) 
AGA † 80 25.7 0.1–395.8  
SGA 88 64.3 0.1–2025.0 < 0.001 
SGA with 
normal UA PI  
32 69.3 0.3–463.5 < 0.001 
”Symmetrical” 
SGA 
29 58.5 0.3–95.9 < 0.001 
 
The bold P values highlight whether the differences observed were statistically significant. 
AGA group serves as a reference (†) when compared separately with the SGA group and the 
SGA with normal UA PI. 
AGA — appropriate for gestational age; SGA — small for gestational age; UA — umbilical 
artery; PI — pulsatility index 
  
Ultrasound examination of central nervous system was performed in all SGA infants 
within first 48 hours of life. Four out of 88 SGA infants had abnormal RI in the anterior 
cerebral artery (< 0.6) in the first head ultrasound examination. 
We found no statistically significant differences in S100B concentration in terms of 
the anterior cerebral artery Doppler scanning between SGA newborns with abnormal RI (< 
0.6) and normal RI (> 0.6). 
 
DISCUSSION 
The study showed that serum S100B concentrations in the SGA infants were higher 




studied S100B levels in cord blood from FGR newborn delivered by elective caesarean 
section and published the first paper about S100B protein and FGR correlation in 2002. In this 
study higher S100B levels in umbilical blood of FGR newborn were demonstrated. 
Since S100B protein, during an active brain injury, is released from a damaged tissue 
into circulation, its concentration increases at an early stage of hypoxia in both cerebrospinal 
fluid and cord blood. The best sources for biomarkers are fluids obtained the least invasively 
and shortly after birth [8]. As S100B protein is highly concentrated in central nervous system, 
and has a half-life about one hour, is released by kidney tissue and increases in biological 
fluids at an early stage. Cord blood and urine seems to be a perfect source for further studies 
of the potential use of S100B measurements in FGR pregnancies and newborns. Gazzolo et al. 
[19], reported that higher concentrations of S100B were detected in cord blood of FGR 
fetuses who developed intraventricular hemorrhage after birth. In addition, the authors 
observed that the highest maternal S100B concentrations were found in group of fetuses with 
prenatal brain-sparing effect in prenatal ultrasound examination. In another study, Florio et 
al., found higher S100B concentrations in urine samples taken shortly after birth in FGR 
newborns compared to matched AGA controls. They noticed highest S100B concentrations in 
the neonates with abnormal neurologic follow-up but also significantly high in FGR infants 
with uneventful neurologic follow-up at one week of age [15]. However, no differences in 
S100B serum concentration of FGR and AGA infants were found in a small study containing 
20 infants in each group [16]. In another study, Gazzolo et al. [13], found a correlation 
between circulating S100B protein and the fetal middle cerebral artery pulsatility index 
(MCA PI) that might suggest cerebral cell damage in growth restricted fetuses. This study 
showed no difference in S100B levels between SGA newborns with no abnormalities in 




In our study, we attempted to investigate whether S100B concentration depends on 
prenatal hemodynamic disturbances. When SGA newborns were grouped according to normal 
and abnormal prenatal UA Doppler examination (UA PI > 95th centile), we did not find any 
differences in serum S100B concentration between either group. In contrast to Gazzolo et al. 
[13], we observed significantly higher S100B concentrations in SGA newborns with normal 
Doppler examination compared to AGA newborns. However, the prenatal ultrasound 
examinations were not performed in all cases and thus these results should be interpreted with 
caution. 
In this study we also divided SGA group according to the traditional biometric birth 
measurements to those with symmetrical and asymmetrical growth restriction. Factors that 
cause symmetric growth restriction tend to develop early during fetal life. Since all SGA 
newborns studied were older than 32 weeks of gestation, we could speculate that beside 
growth restricted newborns, “symmetrical SGA” group included constitutionally and 
physiologically small infants. Both “symmetrical” and “asymmetrical” neonates had higher 
cord blood S100B concentrations compared to AGA neonates but these non-growth restricted 
infants could not be recognized on a group level. 
The importance of biometric as well as functional parameters for identification of FGR 
was reported by Baschat [20], then the consensus-based definition of FGR was established in 
the Delphi criteria [21]. In our study we found that assessment of S100B concentration may 
be helpful in identifying FGR while Doppler findings are normal. Further studies however are 
needed to confirm our results. 
 
CONCLUSIONS 
Increased S100B protein concentration in blood collected from SGA newborns 




restriction. Examination of cord blood S100B concentration may be helpful in identifying 
SGA newborns at a higher risk of postnatal neurological sequelae at an early stage while 
prenatal Doppler examination is normal, standard clinical and laboratory parameters are 
silent, and an early-stage neurologic follow-up is uneventful. 
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